Review |
From the Division of Cardiovascular Medicine (C.C.H., T.K.), Department of Medicine; and Departments of Pharmacology (C.C.H.) and Cell and Developmental Biology (T.K.), Vanderbilt University School of Medicine, Nashville, Tenn; and Cardiovascular Research Center and Division of Cardiology (R.T.P.), Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Charlestown, Mass.
Correspondence to Charles C. Hong, Division of Cardiovascular Medicine, Vanderbilt University Medical Center, 383 PRB, 2220 Pierce Ave, Nashville, TN 37232. E-mail charles.c.hong{at}vanderbilt.edu
This Review is part of a thematic series on Arterial Specification: A Finishing School for the Endothelium, which includes the following articles:
Role of Crosstalk Between Phosphatidylinositol 3-Kinase and Extracellular Signal-Regulated
Kinase/Mitogen-Activated Protein Kinase Pathways in Artery–Vein Specification
Brothers and Sisters: Molecular Insights into Arterial–Venous Heterogeneity
Molecular Mechanisms of Branching Morphogenesis
Fibroblast Growth Factor–Hedgehog Signaling in Coronary Arterial Circulation
Arterial Guidance
Arterial–Venous Specification in Development
Michael Simons Guest Editor
| Abstract |
|---|
|
|
|---|
Key Words: artery–vein specification signaling crosstalk Shh VEGF Notch Fox
| Introduction |
|---|
|
|
|---|
Here, we review recent findings in zebrafish that reveal the genetic program for establishing artery–vein cell identity during embryogenesis. In addition, we discuss relatively novel chemical genetic studies of zebrafish vascular development that have provided evidence that a crosstalk between 2 ubiquitous signaling pathways, the phosphoinositide 3-kinase (PI3K) and the extracellular signal-regulated kinase/mitogen-activated protein kinase (ERK/MAPK) signaling pathways, plays a central antagonistic role in artery–vein specification during vasculogenesis.
| Genetic Control of Artery–Vein Cell Fates in the Zebrafish Embryo |
|---|
|
|
|---|
|
Investigations in the zebrafish have made seminal contributions in defining the molecular pathways required for the acquisition of the arterial cell fate during embryogenesis.11 This pathway involves many of the signaling components known to play important roles in endothelial cell biology, including Sonic hedgehog (Shh), vascular endothelial growth factor (VEGF), Notch, PI3K, and ERK/MAPK signaling.12 Many of these have been shown to have pleiotropic effects essential to diverse aspects of vascular development. For example, Shh, which is expressed in the notochord (a dorsal midline structure),11 and VEGF, which is expressed in somites (future trunk muscles just lateral to the notochord), also serve as extracellular signals critical for the midline migration of angioblasts (Figure 1).13,14
In a series of elegant zebrafish experiments using mRNA and morpholino antisense RNA injections, together with genetic mutants and transgenic embryos, Weinstein and colleagues revealed a genetic hierarchy of several signaling events that induce endothelial arterial fate (Figure 2).11 At the top of this hierarchy is Shh, a member of the Hedgehog family of signaling molecules known to be an indirect angiogenic signal that regulates the expression of VEGF isoforms, and angiopoietin-1 and angiopoietin-2 in interstitial mesenchymal cells.15 In zebrafish, loss of Shh signaling through genetic mutations in syu (sonic-you), encoding Shh, and yot (you-too), encoding its downstream activator Gli2a, or through pharmacological inhibition with cyclopamine results in the loss of the arterial marker Ephrin-B2a and the expansion of the venous marker Flt4 in the vasculature.11 Conversely, overexpression of Shh caused formation of ectopic Ephrin-B2a–expressing presumptive arterial cells within the trunk vessels.
|
Induction of the arterial fate by Shh is mediated by VEGF. VEGF expression in the somites is induced by and dependent on Shh signals from the adjacent notochord. Knockdown of VEGF using morpholino antisense RNA results in the loss of arterial marker Ephrin-B2a expression.11 Conversely, overexpression of VEGF results in upregulation of artery-specific markers and can rescue arterial marker expression in the absence of Shh signals. Although distinct combinations of multiple VEGF receptors are known to be required for the development of different endothelial types in zebrafish, the VEGF receptor-2 homolog Kdra appears to play a dominant role in artery differentiation.16 A forward genetic screen has revealed the involvement of phospholipase C (PLC)
1, a known downstream signaling component of various receptor tyrosine kinases including the VEGF receptors, in the arterial specification pathway. Like embryos lacking VEGF, PLC
1 mutant embryos show specific defects in artery formation.17 Overexpression of VEGF mRNA fails to restore arterial markers, suggesting that PLC
1 is a key downstream transducer of VEGF signals for arterial development. Evidence in zebrafish indicates that Notch signaling acts downstream of both Hedgehog and VEGF signaling to induce the arterial differentiation by suppressing the venous fate. Disruption in Notch signaling through a mutation in mib (mindbomb), necessary for Notch activation, or via expression of dominant-negative Su(H) (suppressor of hairless), a downstream mediator of Notch signaling, abrogates the expression of arterial makers and induces ectopic expression of venous markers.18 Conversely, ectopic activation of Notch signaling by the overexpression of constitutively active Notch intracellular domain [NICD] induces ectopic arterial marker expression and blocks vein marker expression. In addition, activation of Notch signaling can induce ectopic arterial marker expression in the absence of VEGF signaling. However, forced expression of VEGF in mib mutants does not restore artery marker expression, suggesting that Notch acts downstream of VEGF signaling.
Gridlock, a member of the Hairy-related family of transcription factors that act downstream of the Notch signaling, is also involved in artery specification in zebrafish embryos.10 A hypomorphic mutation in the grl (gridlock) (zebrafish hey2 homolog) gene results in a focal defect in the dorsal aorta. Gridlock is first expressed in the lateral plate mesoderm, but its expression becomes restricted to the dorsal aorta. Morpholino knockdown of grl led to progressive loss of dorsal aorta and concomitant enlargement of posterior cardinal vein. Consistent with the role of Gridlock in artery–vein specification, overexpression of Gridlock suppressed venous markers. However, Gridlock overexpression did not result in ectopic expression of artery markers, suggesting that it functions specifically to block the venous state. Whether Gridlock is directly downstream of Notch signaling is unclear because its vascular expression remains intact following expression of dominant-negative Su(H) or in mib mutants.11
| Artery–Vein Specification in Mammals: A Brief Comparative Overview |
|---|
|
|
|---|
Although the roles of Hedgehog and VEGF in artery–vein specification have been elegantly demonstrated in zebrafish, evidence for their involvement in mammalian artery–vein specification during development is less direct. In mice, disruption of Shh, which is expressed in the notochord, does not result in obvious vascular defects.20 Nonetheless, Hedgehog signaling may play a role in arterial specification in mice, as mice lacking Smo (Smoothened), a transmembrane protein that transduces Hedgehog signal, exhibit defective dorsal aorta formation, although this could be attributable to a general defect in endothelial tube formation rather than a primary defect in artery–vein specification.21 In addition, mice with disruptions in Ihh (Indian Hedgehog) or Smo exhibit blocks in remodeling of the yolk sac vasculature, but it is unclear whether this is a consequence of a primary defect in artery–vein specification.22 Mice lacking VEGF or PLC
1 show such a severe disruption in overall vascular development that a definitive conclusion about the direct role of VEGF or PLC
1 in artery–vein specification cannot be made.23,24 However, a more selective perturbation of VEGF expression did result in defective arterial development in the mouse retina.25
In mice, Notch1 and Notch4, as well as Notch ligands Jagged1, Jagged2, Delta-like (Dll)1, and Dll4 are selectively expressed in arterial endothelial cells,26,27 suggesting that Notch signaling is required for arterial identity (reviewed by Roca and Adams28). In support of this notion, the Dll4 ligand is required for mouse artery development in a dose-dependent manner.29 Studies in mice suggest that Gridlock/Hey2 and related Hey1 play an important and redundant role in mouse arterial specification. Although mice with a single knockout of Gridlock homolog Hey2 do not exhibit vascular defects, the compound Hey1:Hey2 double knockout mice show loss of the expression of arterial marker Ephrin-B2.30 Moreover, 2 members of the forkhead/Fox transcription factor family Foxc1 and Foxc2 have recently been shown to be required for artery specification in mice.31 The compound Foxc1:Foxc2 knockout mice show various vascular defects including vascular fusions between the dorsal aorta and the anterior cardinal vein and loss of expression of the arterial markers, such as Dll4. Importantly, Foxc proteins were shown to activate the expression of Dll4, along with other arterial markers such as Hey2, in endothelial cells in vitro. Moreover, Foxc proteins were shown to directly bind to the Dll4 promoter. These and more recent studies, discussed below, demonstrate that Foxc factors play a critical role in linking VEGF signals to the Notch/Hey2 pathway to direct arterial specification.
Collective evidence from zebrafish studies led to a picture in which the venous fate is the default state for bipotent angioblasts and Notch signaling induces arterial development.8 In fact, very little is known regarding the signaling components involved in establishing venous fate identity. Recently, an orphan nuclear receptor COUP-TFII (chicken ovalbumin upstream promoter–transcription factor II) was found to be expressed specifically in venous endothelial cells.32 Endothelial-specific knockout of COUP-TFII led to ectopic expression of arterial markers, and endothelial-specific overexpression of COUP-TFII led to loss of arterial markers. Because manipulations of COUP-TFII expression perturbed expression of arterial-specific Notch pathway markers, it was hypothesized that COUP-TFII functions to maintain venous identity by repressing Notch signaling in venous angioblasts. However, the precise step targeted by COUP-TFII remains unclear because ectopic COUP-TFII expression also disrupted the expression of neuropilin-1 (NP1), a VEGF coreceptor that is normally expressed in arterial cells.33 The role of COUP-TFII in zebrafish artery–vein specification is yet to be determined.
| Chemical Genetic Analysis of Artery–Vein Specification Reveals Opposing Effects of MAPK and PI3K on Artery–Vein Specification |
|---|
|
|
|---|
To complement the genetics studies, small molecule screens were recently performed to identify compounds that suppressed absent trunk circulation because of reduced artery formation in grl mutant embryos.36,37 The central rationale of a chemical suppressor study is analogous to that of classic genetic modifier screen: namely, if impairment in a genetic pathway for arterial development can be suppressed by small molecule, the cellular target of the "chemical suppressor" must be relevant to arterial specification. These screens identified 2 classes of gridlock suppressors. The first class, represented by the compound GS4012, appears to function by activating VEGF signaling. GS4012 induces VEGF expression in zebrafish and mimics the effects of VEGF in zebrafish and in endothelial tubule formation assays. The second class of gridlock suppressors, represented by GS4898, block the PI3K pathway. This was a surprising finding because PI3K is a well-known downstream component of VEGF signaling.38
The apparent paradox of rescue of the identical vascular phenotype by putative stimulators of VEGF signaling, as well as inhibitors of a downstream VEGF signaling component, was resolved with the recognition that 2 well-known signaling pathways activated by the VEGF receptor, the PLC
1-ERK/MAPK pathway and the PI3K-ATK pathways, could play competing or antagonistic roles (Figure 2). In human umbilical vein endothelial cells, the PI3K-AKT pathway has been shown to antagonize ERK/MAPK signaling.39 Moreover, in a human breast cancer cell line, similar PI3K-AKT and ERK/MAPK crosstalk occurred through direct inhibitory phosphorylation of Raf, a MAPK signaling component, by AKT, a key kinase acting downstream of PI3K.40 In zebrafish embryos, incubation with GS4898 or known P3K inhibitors, LY294002 and wortmannin, results in activation of the ERK/MAPK and expansion of the arterial fate.37 Conversely, inhibition of mitogen/extracellular signal-activated protein kinase kinase (MEK), an upstream activator of ERK, results in loss of arterial structures. To circumvent the pleiotropic effects of ERK/MAPK and PI3K/AKT in early development, mosaic transgenic expression of AKT in zebrafish were used to confirm chemical genetic findings. Expression of dominant negative AKT along with green fluorescent protein (GFP) resulted in preferential localization of GFP-positive cells in the dorsal aorta, whereas expression of constitutively active AKT resulted in localization of GFP-positive cells in the posterior cardinal vein. Together, these results suggest that ERK/MAPK signaling is required for the arterial cell fate, whereas PI3K signaling has an opposing effect of promoting the venous fate by inhibiting the ERK/MAPK pathway.
Importantly, during zebrafish development, activated/phosphorylated ERK is localized precisely to dorsal angioblasts that will develop into aortic endothelial cells but not ventral angioblasts destined to become venous endothelial cells (Figure 3).37 Pharmacological blockade of VEGF receptor-1 and -2 signaling, and of Hedgehog signaling, both of which block arterial specification, were shown to prevent ERK activation in endothelial progenitors. Conversely, high concentrations of PI3K inhibitors were shown to expand ERK activation within endothelial progenitors. These results show that Hedgehog and VEGF signaling are required upstream of ERK/MAPK pathway to activate it specifically in arterial progenitors and that ERK activation is among the earliest known markers and determinants of artery cell fate in zebrafish embryos. Of note, strikingly analogous aorta-specific ERK activation has also been observed in mouse embryos,41 suggesting a similar role for ERK signaling in mouse arterial development.
|
Interestingly, the earliest detection of ERK activation occurs even before the completion of angioblast migration to the midline (15 hpf; Figure 4).37 During angioblast migration, activated ERK is preferentially localized to a distinct subset of angioblasts on the leading edge (Figure 4), which, on time-lapse micrography, appear to contribute to the nascent dorsal aorta (C. Hong and R.T. Peterson, unpublished observations, 2008). Such early emergence of distinct arterial and venous angioblasts, which exhibit different migratory timing, is consistent with the findings in synectin-deficient zebrafish, in which selective disturbance in angioblast migration precede the deficient artery differentiation.42 These results are consistent with cell lineage tracing experiments that suggest that artery–vein fate is already established when angioblasts begin their midline migration from their origins in the lateral plate mesoderm.10 Lastly, activated ERK is not detected after the circulation is established, suggesting that ERK activation is not required for maintenance of the arterial phenotype in zebrafish.
|
| Crosstalk Between PI3K and MAPK in Mammalian Systems: Comparison to Zebrafish Findings |
|---|
|
|
|---|
, resulting in activation of protein kinase C and Raf, which then triggers a kinase activation cascade leading to ERK/MAPK activation and promoting endothelial cell proliferation. In most in vitro contexts, the 2 branches are stimulated by VEGF together and often act in a synergistic manner. Nonetheless, in certain endothelial culture systems, the PI3K branch has been shown to antagonize the PLC
-ERK/MAPK branch, similar to the observations in zebrafish embryos.39 In vitro mammalian cell studies have uncovered important differences from in vivo zebrafish studies regarding interactions between VEGF, Notch, and ERK signaling. In cultured human arterial endothelial cells, VEGF signal induces expression of Notch1 and Dll4.44 However, in contrast to the zebrafish data, VEGF-induced Notch activation is mediated by PI3K, rather than ERK/MAPK.44 Additional studies in bovine aortic endothelial cells have demonstrated that Foxc transcription factors mediate VEGF signaling by directly activating Dll4 and Hey2 promoters.45 Moreover, VEGF-activated PI3K and ERK pathways were found to modulate the transcriptional activation of Dll4 and Hey2 genes by Foxc proteins. Again in contrast to the zebrafish data, the PI3K pathway was found to be necessary for inducing Dll4 and Hey2 expression. Interestingly, the ERK pathway was found to repress Dll4 and Hey2 expression, supporting the presence of a functional ERK-PI3K crosstalk in aortic endothelial cells. Reasons for the discrepancy between in vitro and in vivo data regarding the functional effects of ERK and PI3K crosstalk are unclear. One possible explanation is that these in vitro experiments were all done in endothelial cells with a well-established arterial cell identify, not in uncommitted bipotent endothelial progenitor cells. In addition, as mentioned earlier, ERK activation in arterial progenitor cells is noted over the course of several hours, a far longer time frame than the transient ERK activation observed in cultured endothelial cells following VEGF stimulation. Thus, there may be important fundamental differences in ERK activation between in vivo and in vitro models. Finally, in a mouse ES cell model of in vitro differentiation of artery and vein cell types, higher concentrations of VEGF promoted expression of arterial marker genes, whereas low and intermediate levels of VEGF preferentially induced expression of the venous marker COUP-TFII.46 Moreover, this VEGF-dependent arterial development could be blocked by Notch signal inhibition. Whether graded VEGF signaling could govern preferential activation of either PI3K or ERK pathways was not tested in this model. In summary, although interactions between VEGF, Notch, and ERK signaling in isolated endothelial cells in culture may not fully recapitulate complex multicellular interactions that occur in the developing embryo, recent evidence supports the existence of a crosstalk between PI3K and ERK, with functional implications for artery–vein specification.
| Concluding Remarks |
|---|
|
|
|---|
The chemical genetic approach was recently used to reveal previously unsuspected roles of PI3K and ERK, 2 well-known VEGF signaling branches, in artery–vein specification. These findings raise additional interesting questions. For example, what determines whether an angioblast activates ERK or PI3K signaling? Could particular VEGF receptor subtypes or VEGF gradient govern which signaling branch is activated? What are the downstream targets of the ERK and PI3K signaling involved in artery–vein specification? Another important question regards whether the crosstalk between PI3K and ERK also plays an analogous role in specification of artery–vein fates in mammals. Although studies in cultured mammalian cells have yielded contradictory results, an earlier finding of localized activation of ERK in the developing aorta in mouse embryos41 suggests a conserved role for ERK in mammalian arterial specification. Further studies using classic and chemical genetics in zebrafish, as well as in vivo and in vitro mammalian models, will be necessary to resolve whether the discrepancy is attributable to a fundamental species difference or to a difference between in vivo and in vitro models. Finally, although genetic programs play a critical role in artery–vein specification during development, local environmental factors such as shear stress are also known to modify artery and vein cell identity.47–49 Curiously, in the setting of adaptation after femoral artery occlusion, sustained shear stress promotes collateral artery growth, in part, by activating the ERK pathway.50 Thus, it will be interesting, and clinically relevant, to examine whether the influence of environmental factors on artery–vein plasticity involves the signaling components implicated in artery–vein specification during development.
| Acknowledgments |
|---|
This work was supported by NIH grants HL081535 (to C.C.H.), HL074121 (to T.K.), and HL079267 (to R.T.P.) and a grant from the GlaxoSmithKline Research & Education Foundation for Cardiovascular Research (to C.C.H.).
Disclosures
None.
| Footnotes |
|---|
| References |
|---|
|
|
|---|
2. Guttmacher AE, Marchuk DA, White RIJ. Hereditary hemorrhagic telangiectasia. N Engl J Med. 1995; 333: 918–924.
3. Grundwald DJ, Eisen JS. Headwaters of the zebrafish - emergence of a new model vertebrate. Nat Rev Genet. 2002; 3: 717–724.[Medline] [Order article via Infotrieve]
4. Thisse C, Zon LI. Organogenesis - heart and blood formation from the zebrafish point of view. Science. 2002; 295: 457–462.
5. Thompson MA, Ransom DG, Pratt SJ, MacLennan H, Kieran MW, Detrich HW, Gates MA, Amores A, Bahary N, Talbot WS, Her H, Beier DR, Postlethwait JH, Zon LI. The cloche and spadetail genes differentially affect hematopoiesis and vasculogenesis. Dev Biol. 1998; 197: 248–269.[CrossRef][Medline] [Order article via Infotrieve]
6. Eriksson J, Lofberg J. Development of the hypochord and dorsal aorta in the zebrafish embryo (Danio rerio). J Morphol. 2000; 244: 167–176.[CrossRef][Medline] [Order article via Infotrieve]
7. Fourquet B, Weinstein BM, Serluca FC, Fishman MC. Vessel patterning in the embryo of the zebrafish: guidance by notochord. Dev Biol. 1997; 183: 37–48.[CrossRef][Medline] [Order article via Infotrieve]
8. Lawson ND, Weinstein BM. Arteries and veins: making a difference with zebrafish. Nat Rev Genet. 2002; 3: 674–682.[CrossRef][Medline] [Order article via Infotrieve]
9. Mukhopadhyay A, Peterson RT. Deciphering arterial identity through gene expression, genetics, and chemical biology. Curr Opin Hematol. 2008; 15: 221–227.[CrossRef][Medline] [Order article via Infotrieve]
10. Zhong TP, Childs S, Leu JP, Fishman MC. Gridlock signalling pathway fashions the first embryonic artery. Nature. 2001; 414: 216–220.[CrossRef][Medline] [Order article via Infotrieve]
11. Lawson ND, Vogel AM, Weinstein BM. Sonic hedgehog and vascular endothelial growth factor act upstream of the Notch pathway during arterial endothelial differentiation. Dev Cell. 2002; 3: 127–136.[CrossRef][Medline] [Order article via Infotrieve]
12. Lamont RE, Childs S. MAPping out arteries and veins. Sci STKE. 2006; 2006: pe39.
13. Cleaver O, Krieg PA. VEGF mediates angioblast migration during development of the dorsal aorta. Development. 1998; 125: 3905–3914.[Abstract]
14. Gering M, Patient R. Hedgehog signaling is required for adult blood stem cell formation in zebrafish embryos. Dev Cell. 2005; 8: 389–400.[CrossRef][Medline] [Order article via Infotrieve]
15. Pola R, Ling LE, Silver M, Corbley MJ, Kearney M, Blake Pepinsky R, Shapiro R, Taylor FR, Baker DP, Asahara T, Isner JM. The morphogen Sonic hedgehog is an indirect angiogenic agent upregulating two families of angiogenic growth factors. Nat Med. 2001; 7: 706–711.[CrossRef][Medline] [Order article via Infotrieve]
16. Covassin LD, Villefranc JA, Kacergis MC, Weinstein BM, Lawson ND. Distinct genetic interactions between multiple Vegf receptors are required for development of different blood vessel types in zebrafish. Proc Natl Acad Sci U S A. 2006; 103: 6554–6559.
17. Lawson ND, Mugford JW, Diamond BA, Weinstein BM. phospholipase C gamma-1 is required downstream of vascular endothelial growth factor during arterial development. Genes Dev. 2003; 7: 1346–1351.
18. Lawson ND, Scheer N, Pham V, Kim C-H, Chitnie AB, Campos-Ortega J, Weinstein BM. Notch signaling is required for arterial-venous differentiation during embryonic vascular development. Development. 2001; 128: 3675–3683.
19. Coultas L, Chawengsaksophak K, Rossant J. Endothelial cells and VEGF in vascular development. Nature. 2005; 438: 937–945.[CrossRef][Medline] [Order article via Infotrieve]
20. Chiang C, Litingtung Y, Lee E, Young KE, Corden JL, Westphal H, Beachy PA. Cyclopia and defective axial patterning in mice lacking Sonic hedgehog gene function. Nature. 1996; 383: 407–413.[CrossRef][Medline] [Order article via Infotrieve]
21. Vokes SA, Yatskievych TA, Heimark RL, McMahon J, McMahon AP, Antin PB, Krieg PA. Hedgehog signaling is essential for endothelial tube formation during vasculogenesis. Development. 2004; 131: 4371–4380.
22. Byrd N, Becker S, Maye P, Narasimhaiah R, St-Jacques B, Zhang X, McMahon J, McMahon A, Grabel L. Hedgehog is required for murine yolk sac angiogenesis. Development. 2002; 129: 361–372.[Medline] [Order article via Infotrieve]
23. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, Declercq C, Pawling J, Moons L, Collen D, Risau W, Nagy A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature. 1996; 380: 435–439.[CrossRef][Medline] [Order article via Infotrieve]
24. Liao HJ, Kume T, McKay C, Xu MJ, Ihle JN, Carpenter G. Absence of erythrogenesis and vasculogenesis in Plcg1-deficient mice. J Biol Chem. 2002; 277: 9335–9341.
25. Stalmans I, Ng YS, Rohan R, Fruttiger M, Bouche A, Yuce A, Fujisawa H, Hermans B, Shani M, Jansen S, Hicklin D, Anderson DJ, Gardiner T, Hammes HP, Moons L, Dewerchin M, Collen D, Carmeliet P, D'Amore PA. Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. J Clin Invest. 2002; 109: 327–336.[CrossRef][Medline] [Order article via Infotrieve]
26. Villa N, Walker L, Lindsell CE, Gasson J, Iruela-Arispe ML, Weinmaster G. Vascular expression of Notch pathway receptors and ligands is restricted to arterial vessels. Mech Dev. 2001; 108: 161–164.[CrossRef][Medline] [Order article via Infotrieve]
27. Limbourg A, Ploom M, Elligsen D, Sorensen I, Ziegelhoeffer T, Gossler A, Drexler H, Limbourg FP. Notch ligand Delta-like 1 is essential for postnatal arteriogenesis. Circ Res. 2007; 100: 363–371.
28. Roca C, Adams RH. Regulation of vascular morphogenesis by Notch signaling. Genes Dev. 2007; 21: 2511–2524.
29. Duarte A, Hirashima M, Benedito R, Trindade A, Diniz P, Bekman E, Costa L, Henrique D, Rossant J. Dosage-sensitive requirement for mouse Dll4 in artery development. Genes Dev. 2004; 18: 2474–2478.
30. Fischer A, Schumacher N, Maier M, Sendtner M, Gessler M. The Notch target genes Hey1 and Hey2 are required for embryonic vascular development. Genes Dev. 2004; 18: 901–911.
31. Seo S, Fujita H, Nakano A, Kang M, Duarte A, Kume T. The forkhead transcription factors, Foxc1 and Foxc2, are required for arterial specification and lymphatic sprouting during vascular development. Dev Biol. 2006; 294: 458–470.[CrossRef][Medline] [Order article via Infotrieve]
32. You LR, Lin FJ, Lee CT, DeMayo FJ, Tsai MJ, Tsai SY. Suppression of Notch signalling by the COUP-TFII transcription factor regulates vein identity. Nature. 2005; 435: 98–104.[CrossRef][Medline] [Order article via Infotrieve]
33. Mukouyama YS, Gerber HP, Ferrara N, Gu C, Anderson DJ. Peripheral nerve-derived VEGF promotes arterial differentiation via neuropilin 1-mediated positive feedback. Development. 2005; 132: 941–952.
34. McMahon AP, Ingham PW, Tabin CJ. Developmental roles and clinical significance of hedgehog signaling. Curr Top Dev Biol. 2003; 53: 1–114.[Medline] [Order article via Infotrieve]
35. Ihle JN. The challenges of translating knockout phenotypes into gene function. Cell. 2000; 102: 131–134.[CrossRef][Medline] [Order article via Infotrieve]
36. Peterson RT, Shaw SY, Peterson TA, Milan DJ, Zhong TP, Schreiber SL, MacRae CA, Fishman MC. Chemical suppression of a genetic mutation in a zebrafish model of aortic coarctation. Nat Biotechnol. 2004; 22: 595–599.[CrossRef][Medline] [Order article via Infotrieve]
37. Hong CC, Peterson QP, Hong JY, Peterson RT. Artery/vein specification is governed by opposing phosphatidylinositol-3 kinase and MAP kinase/ERK signaling. Curr Biol. 2006; 16: 1366–1372.[CrossRef][Medline] [Order article via Infotrieve]
38. Zachary I, Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res. 2001; 49: 568–581.
39. Blum S, Issbruker K, Willuweit A, Hehlgans S, Lucerna M, Mechtcheriakova D, Walsh K, von der Ahe D, Hofer E, Clauss M. An inhibitory role for the phosphatidylinositol 3-kinase-signaling pathway in vascular endothelial growth factor-induced tissue factor expression. J Biol Chem. 2001; 276: 33428–33434.
40. Zimmermann S, Moelling K. Phosphorylation and regulation of Raf by Akt (protein kinase B). Science. 1999; 286: 1741–1744.
41. Corson LB, Yamanaka Y, Lai KM, Rossant J. Spatial and temporal patterns of ERK signaling during mouse embryogenesis. Development. 2003; 130: 4527–4537.
42. Chittenden TW, Claes F, Lanahan AA, Autiero M, Palac RT, Tkachenko EV, Elfenbein A, Ruiz de Almodovar C, Dedkov E, Tomanek R, Li W, Westmore M, Singh JP, Horowitz A, Mulligan-Kehoe MJ, Moodie KL, Zhuang ZW, Carmeliet P, Simons M. Selective regulation of arterial branching morphogenesis by synectin. Dev Cell. 2006; 10: 783–795.[CrossRef][Medline] [Order article via Infotrieve]
43. Takahashi T, Ueno H, Shibuya M. VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene. 1999; 18: 2221–2230.[CrossRef][Medline] [Order article via Infotrieve]
44. Liu ZJ, Shirakawa T, Li Y, Soma A, Oka M, Dotto GP, Fairman RM, Velazquez OC, Herlyn M. Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis. Mol Cell Biol. 2003; 23: 14–25.
45. Hayashi H, Kume T. Foxc transcription factors directly regulate Dll4 and Hey2 expression by interacting with the VEGF-Notch signaling pathways in endothelial cells. PLoS ONE. 2008; 3: e2401.[CrossRef]
46. Lanner F, Sohl M, Farnebo F. Functional arterial and venous fate is determined by graded VEGF signaling and notch status during embryonic stem cell differentiation. Arterioscler Thromb Vasc Biol. 2007; 27: 487–493.
47. Moyon D, Pardanaud L, Yuan L, Breant C, Eichmann A. Plasticity of endothelial cells during arterial-venous differentiation in the avian embryo. Development. 2001; 128: 3359–3370.
48. le Noble F, Moyon D, Pardanaud L, Yuan L, Djonov V, Matthijsen R, Breant C, Fleury V, Eichmann A. Flow regulates arterial-venous differentiation in the chick embryo yolk sac. Development. 2004; 131: 361–375.
49. Othman-Hassan K, Patel K, Papoutsi M, Rodriguez-Niedenfuhr M, Christ B, Wilting J. Arterial identity of endothelial cells is controlled by local cues. Dev Biol. 2001; 237: 398–409.[CrossRef][Medline] [Order article via Infotrieve]
50. Eitenmuller I, Volger O, Kluge A, Troidl K, Barancik M, Cai WJ, Heil M, Pipp F, Fischer S, Horrevoets AJ, Schmitz-Rixen T, Schaper W. The range of adaptation by collateral vessels after femoral artery occlusion. Circ Res. 2006; 99: 656–662.
This article has been cited by other articles:
![]() |
T. Masumura, K. Yamamoto, N. Shimizu, S. Obi, and J. Ando Shear Stress Increases Expression of the Arterial Endothelial Marker EphrinB2 in Murine ES Cells via the VEGF-Notch Signaling Pathways Arterioscler Thromb Vasc Biol, December 1, 2009; 29(12): 2125 - 2131. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Torella, C. Gasparri, G. M. Ellison, A. Curcio, A. Leone, C. Vicinanza, V. Galuppo, I. Mendicino, W. Sacco, I. Aquila, et al. Differential regulation of vascular smooth muscle and endothelial cell proliferation in vitro and in vivo by cAMP/PKA-activated p85{alpha}PI3K Am J Physiol Heart Circ Physiol, December 1, 2009; 297(6): H2015 - H2025. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2008 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |